204 related articles for article (PubMed ID: 7805371)
41. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users.
Brill K; Norpoth T; Schnitker J; Albring M
Contraception; 1991 Feb; 43(2):101-10. PubMed ID: 2040166
[TBL] [Abstract][Full Text] [Related]
42. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 microg ethinyl estradiol and 150 microg desogestrel in Latin-American women.
Comparato MR; Yabur JA; Bajares M
Adv Contracept; 1998 Mar; 14(1):15-26. PubMed ID: 9587005
[TBL] [Abstract][Full Text] [Related]
43. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
[TBL] [Abstract][Full Text] [Related]
44. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO; op ten Berg MT; Coelingh Bennink HJ
Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
[TBL] [Abstract][Full Text] [Related]
45. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
Dieben TO; van Beek A; Coelingh Bennink HJ
Arzneimittelforschung; 1991 Sep; 41(9):996-8. PubMed ID: 1839126
[TBL] [Abstract][Full Text] [Related]
46. Clinical experience in Switzerland with the new monophasic oral contraceptive Minulet (75 mcg gestodene, 30 mcg ethinyl oestradiol).
Privrel T; Daubenfeld O
Br J Clin Pract; 1988 Jul; 42(7):292-8. PubMed ID: 3075505
[TBL] [Abstract][Full Text] [Related]
47. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
Norris LA; Devitt M; Bonnar J
Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
[TBL] [Abstract][Full Text] [Related]
48. Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease.
Di Lieto A; De Rosa G; Albano G; Pagnano AM; Campanile M; Terracciano L; Pontillo M; Cimmino E; Covelli A; Paladini A
Eur J Obstet Gynecol Reprod Biol; 1994 May; 55(1):71-83. PubMed ID: 7958144
[TBL] [Abstract][Full Text] [Related]
49. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
Wilde MI; Balfour JA
Drugs; 1995 Aug; 50(2):364-95. PubMed ID: 8521763
[TBL] [Abstract][Full Text] [Related]
50. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
Bonnar J; Daly L; Carroll E
Int J Fertil; 1987; 32 Suppl():21-8. PubMed ID: 2906344
[TBL] [Abstract][Full Text] [Related]
51. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.
Serfaty D; Vree ML
Eur J Contracept Reprod Health Care; 1998 Dec; 3(4):179-89. PubMed ID: 10036600
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Kuhnz W; Schütt B; Power J; Back DJ
Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
[TBL] [Abstract][Full Text] [Related]
53. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Kaunitz AM
Contraception; 2000 May; 61(5):295-302. PubMed ID: 10906499
[TBL] [Abstract][Full Text] [Related]
54. Clinical and metabolic effects of gestodene and levonorgestrel.
Rabe T; Runnebaum B; Kohlmeier M; Harenberg J; Weicker H
Int J Fertil; 1987; 32 Suppl():29-44. PubMed ID: 2906345
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism.
Jung-Hoffman C; Kuhl H
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2183-97. PubMed ID: 2147819
[TBL] [Abstract][Full Text] [Related]
56. Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval.
Archer DF
Contraception; 1999 Sep; 60(3):151-4. PubMed ID: 10640158
[TBL] [Abstract][Full Text] [Related]
57. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: results of a multicenter clinical study.
Skouby SO
Int J Fertil; 1987; 32 Suppl():45-8. PubMed ID: 2906346
[TBL] [Abstract][Full Text] [Related]
58. [Clinical experiences with femovan (Gynera)].
Brill K; Düsterberg B; Albring M
Ther Umsch; 1990 Dec; 47(12):958-65. PubMed ID: 2096480
[TBL] [Abstract][Full Text] [Related]
59. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
60. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.
Lüdicke F; Gaspard UJ; Demeyer F; Scheen A; Lefebvre P
Contraception; 2002 Dec; 66(6):411-5. PubMed ID: 12499033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
